Bellerophon Therapeutics Inc

Bellerophon Therapeutics — Technical Presentation (September 2015)

18 slides from Bellerophon Therapeutics's technical presentation, Sep 25, 2015

  1. Slide 1: Interim Analysis of INOpulse PAH Long-Term Extension Study (PAH-201)

    Interim Analysis of INOpulse Pulmonary Arterial Hypertension Long-Term Extension Study (PAH-201) September, 2015

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financi

  3. Slide 3: Part 2 of INOpulse PAH Phase 2 Study

    Part 2 of INOpulse PAH Phase 2 Study Month 4 iNO 75 Screening Randomization iNO 25 Placebo iNO 75 iNO 25 Randomization Long Term Extension Study Following 16 weeks of blinded therapy (Part 1) placebo subjects were randomized to receive either 25 mcg/kg/IBD per hour (iNO 25) or iNO 75; treated patien

  4. Slide 4: PAH Therapy at Start of Part 2

    PAH Therapy at Start of Part 2 iNO 25 iNO 75 Total Monotherapy 9 (28%) 7 (21%) 16 (24%) Dual Therapy 16 (50% 15 (46%) 31 (48%) Triple Therapy 7 (22%) 11 (33%) 18 (28%) IV Prostacyclin 12 (38%) 19 (58%) 31 (48%)

  5. Slide 5: Change in 6MWD with iNO 25 and iNO 75 with LTOT

    Change in 6MWD with 8 to 12 months of Treatment with iNO 25 and iNO 75 with LTOT 6MWD (meters) N Mean SE iNO 25 16 17.8 11.8 iNO 75 20 31.6 13.2 % 6MWD 50 meters N % iNO 25 16 31.3 iNO 75 20 50 0 5 10 15 20 25 30 35 iNO 25 iNO 75 Change 6MWD (meters) 0 10 20 30 40 50 60 iNO 25 iNO 75 Percentage Subj

  6. Slide 6: Change in PVR with iNO 25 and iNO 75 with LTOT

    Change in PVR with 8 to 12 months of Treatment with iNO 25 and iNO 75 with LTOT PVR (dynes.sec.cm-5) N Mean SE iNO 25 13 -65.5 48.9 iNO 75 14 -87.3 53.7 Percentage PVR -20% N % iNO 25 13 30.8 iNO 75 14 50 -100 -90 -80 -70 -60 -50 -40 -30 -20 -10 0 iNO 25 iNO 75 Change PVR (dynes.sec.cm - 5 ) 0 10 20

  7. Slide 7: LTOT Patients on Placebo in Part 1 Who Transferred to iNO Did Particularly Well

    LTOT Patients on Placebo in Part 1 Who Transferred to iNO 75 Did Particularly Well Change PVR 4 to 12 months: -376 dynes.sec.cm-5 (n=4)

  8. Slide 8: LTOT Patients on iNO Showed Improvements in WHO Functional Class

    LTOT Patients on iNO 75 Showed Improvements in WHO Functional Class N=1 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Baseline 12 months iNO 75 in LTOT patients IV III II I N=3 N=16 N=1 N=1 N=6 N=12 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Baseline 12 months iNO 25 in LTOT patients IV III II I N=4

  9. Slide 9: LTOT Patients on iNO Who Stayed on Therapy for 12 Hours a Day Improved Even More

    LTOT Patients on iNO 75 Who Stayed on Therapy for 12 hours a Day Improved Even More 6MWD (meters) N MEAN SE iNO 75 < 12 hrs 9 19.6 21.9 iNO 75 12 hrs 11 41.4 16.4

  10. Slide 10: Improvements in 6MWD Were Not Correlated with Changes in PAH Therapies

    Improvements in 6MWD Were Not Correlated with Changes in PAH Therapies Medications Added in Part 2 iNO 25 iNO 75 Added 1 oral medication 4 0 Added IV prostacyclin 3 0 10% increase in prostacyclin dose 1 0

  11. Slide 11: Inconsistent Results for Patients Not on LTOT

    Inconsistent Results for Patients Not on LTOT 6MWD (meters) N Mean SE iNO 25 10 2.4 22.7 iNO 75 11 -16.3 18.7 PVR (dynes.sec.cm-5) N Mean SE iNO 25 6 -155 92.5 iNO 75 9 44.8 58.8 -200 -150 -100 -50 0 50 100 150 200 iNO 25 iNO 75 Change PVR ( dynes.sec.cm - 5 ) -35 -25 -15 -5 5 15 25 35 iNO 25 iNO 75

  12. Slide 12: Reminder: LTOT Patients on iNO Improved in 6MWD and PVR in Part 1

    As a Reminder: LTOT Patients on iNO 75 Also Demonstrated Improvement in 6MWD and PVR in Part 1 of the Phase II Study * p<0.05 vs. placebo LTOT Patients N 6MWD (meters) PVR (dynes.sec.cm-5) Placebo 10 -10.7 125.5 iNO 25 15 9.1 -47.1 iNO 75 18 34.9 -17.5 -100 -50 0 50 100 150 Placebo iNO 25 iNO 75 Cha

  13. Slide 13: Hypothesis for Phase III Trial

    Hypothesis for Phase III Trial The outcome of this interim analysis supports the hypothesis generated in Part 1 of the Phase 2 study The optimal benefit of iNOpulse is with the iNO 75 dose in patients on LTOT who stay on the therapy for at least 12 hours each day This is the population that will be

  14. Slide 14: Phase III Protocol

    Phase III Protocol Two Trials: One with 2 arms (iNO 75 and Placebo) One with 3 arms (iNO 75, iNO 50, and Placebo) Each arm will comprise approximately 90 subjects All subjects will be on LTOT The Primary endpoint is improvement in 6MWD compared to the placebo arm after 16 weeks The Secondary endpoin

  15. Slide 15: INOpulse Mark is Substantially Lighter and More Intuitive

    INOpulse Mark 2 is Substantially Lighter and More Intuitive ~8 lbs. in weight LCD display with multiple menus/settings designed for use by RT’s in hospital Needs a backpack or wheeled bag to carry ~2.5 lbs. in weight Easy to use user interface Fits in small hip/shoulder bag; Per usability testing, p

  16. Slide 16: Additional Work Planned in COPD and IPF in 2015/2016

    Additional Work Planned in COPD and IPF in 2015/2016 INOpulse Exploratory Studies PH-COPD PH-COPD: RHC measurements during exercise +/- iNO (n=5) Open Label 4 week iNO trial with 6MWT f/b 2 week washout (n=10) PH-IPF Acute iNO vs. Placebo Imaging of Vasodilation (n=4) Open Label 4 week iNO trial wit

  17. Slide 17: THANK YOU

    THANK YOU THERAPEUTICS.

  18. Slide 18: Efficacy of Other Approved Drugs for Reference

    Efficacy of Other Approved Drugs for Reference WHO = world health organization, NYHA = New York Heart Association, OL = open label, ERAs = endothelin receptor antagonist, PGI2s = prostacyclin analogues, PDE5Is= phosphodiesterase type 5 inhibitors, = approximately, * indicates borderline significance

Bellerophon Therapeutics — Technical Presentation (September 2015) on 6ix